Phrixus Pharmaceuticals
  • European Access Program
    for Carmeseal-MD™
  • Our People
    • Management
    • Board of Directors
    • Scientific and Medical Advisory Board
  • Product Background
    • Preclinical Efficacy Results
    • Preclinical Safety Results
    • Previous Human Experience
  • Indications
  • Contact

Our People

Phrixus’s management team and board of directors have experience in both major pharmaceutical companies and entrepreneurial biotechnology companies.

Management

Board of Directors

Scientific and Medical Advisory Board

Share

Latest News

  • Phrixus Pharmaceuticals announces Phase 2 clinical trial of Poloxamer 188 NF in non-ambulatory patients with Duchenne muscular dystrophy
  • Phrixus Pharmaceuticals announces the first patient with Duchenne muscular dystrophy (DMD) to meet the 15-month mark on Carmeseal-MD™ (Poloxamer 188 NF)
  • FDA allows Phrixus’s IND for Carmeseal-MD™ (P-188 NF) in Duchenne muscular dystrophy (DMD)
  • Carmeseal-MD™, the first disease-modifying agent for skeletal limb muscle, diaphragm and heart
  • Independent study confirms hypothesized mechanism of action for Carmeseal-MD™ (P-188 NF) as membrane sealant on dystrophic cells
  • Carmeseal-MD™ (P-188 NF) improves respiratory and cardiac dysfunction in dystrophic mice after subcutaneous administration
  • Phrixus Pharmaceuticals Receives Services from NIH
  • Phrixus Pharmaceuticals Announces European Access Program
  • Phrixus Pharmaceuticals Announces SMARTT/NHLBI Award
  • Phrixus Pharmaceuticals Announces Funding by DuchenneDashboard
  • Phrixus Pharmaceuticals Reports Positive Preclinical Results
  • Phrixus Pharmaceuticals Announces $623,000 in NIH Funding
  • Phrixus Pharmaceuticals Announces $890,000 in NIH Funding
  • Facebook
  • Twitter
  • RSS